This Article Full Text Full Text (PDF) Erratum (v23,p7763) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Farray, D. Articles by Albain, K. S. Search for Related Content PubMed PubMed Citation Articles by Farray, D. Articles by Albain, K. S.

Multimodality Therapy for Stage III Non–Small-Cell Lung Cancer

Daniel Farray, Nena Mirkovic, Kathy S. Albain

From the Loyola University Chicago Medical Center, Maywood, IL

Address reprint requests to Kathy S. Albain, MD, Loyola University Medical Center, Cardinal Bernardin Cancer Center, 2160 South First Avenue, Maywood, IL 60153-5589; e-mail: kalbain{at}lumc.edu.

The treatment of stage III non–small-cell lung cancer has evolved over the last two decades, with combined-modality therapy the current standard of care. As a result, intermediate and long-term survival has improved for patients in this common stage category, compared to the poor outcomes achieved with the historical standard of once-daily radiation therapy alone. This review summarizes two decades of clinical research regarding bimodality and trimodality approaches for the heterogenous stage subsets within the stage III designation, discusses the rationale and status of prophylactic brain irradiation, and concludes with perspectives on progress and future directions. Chemotherapy plus radiotherapy given concurrently is the optimal treatment for the group of patients with advanced stage III disease. The potential role of a surgical resection following chemotherapy (with or without radiation) in this setting is still controversial. The only subsets for which trimodality treatments are clearly preferred include T4N0-1 disease and superior sulcus tumors. The other major stage III subgroup has a minimal disease burden with low tumor volume and/or microscopic N2 disease, thus technically could undergo a surgical resection upfront. Induction chemotherapy before surgery may yield a survival advantage, although the phase III trials in this area are not conclusive. Given the marked survival benefit from adjuvant chemotherapy after surgery in even earlier stages of non–small-cell lung cancer, the proper sequence of surgery and chemotherapy (before v after surgery) remains an important unresolved question in this subgroup. Furthermore, how to incorporate radiation therapy, as well as whether it should be given at all in this subset of patients, are other important issues actively under study in ongoing trials.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				A. DiFeo, L. Feld, E. Rodriguez, C. Wang, D. G. Beer, J. A. Martignetti, and G. Narla A Functional Role for KLF6-SV1 in Lung Adenocarcinoma Prognosis and Chemotherapy Response Cancer Res., February 15, 2008; 68(4): 965 - 970. [Abstract] [Full Text] [PDF]

				D. H. Johnson, V. W. Rusch, and A. T. Turrisi Scalpels, Beams, Drugs, and Dreams: Challenges of Stage IIIA-N2 Non-Small-Cell Lung Cancer J Natl Cancer Inst, March 21, 2007; 99(6): 415 - 418. [Full Text] [PDF]

				S.-i. Takeda, H. Maeda, T. Okada, T. Yamaguchi, M. Nakagawa, S. Yokota, N. Sawabata, and M. Ohta Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer. Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 184 - 189. [Abstract] [Full Text] [PDF]

				T. E. Stinchcombe, D. Fried, D. E. Morris, and M. A. Socinski Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer Oncologist, July 1, 2006; 11(7): 809 - 823. [Abstract] [Full Text] [PDF]